Compare iShares Core MSCI EAFE ETF (IEFA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.33 (market cap $189.19B), while Neurocrine Biosciences Inc trades at $142.88 (market cap $14.36B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 13.2× Neurocrine Biosciences Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IEFA | NBIX | |
|---|---|---|
Market Cap | $189.19B | $14.36B |
Volume | 8,441,787 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $185.50 |
52-Week Low | $85.06 | $123.10 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $96.18, down 0.02% on the day, with a bearish technical outlook indicated by moving averages and oscillators. The ETF, managed by BlackRock, holds $196 billion in assets and focuses on developed markets outside North America. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower expense ratio relative to some peers, though performance has lagged behind certain total-world and emerging market funds over the past year.
The outlook for IEFA is clouded by technical weakness and competitive pressures, though its scale and cost efficiency offer stability. Key risks include concentration in developed markets, which may underperform during global growth shifts, and the impact of geopolitical tensions on international equities. Analyst sentiment is mixed, with the fund's defensive characteristics balancing against limited near-term catalysts.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
